Key result
Percutaneous revascularization in NSTEMI patients with prior CABG was associated with adjusted 30-day and 1-year mortality similar to patients without prior CABG, regardless of the target vessel.
Why the study?
Does PCI target (native vessel vs bypass graft) affect mortality in NSTEMI patients with prior CABG compared to those without prior CABG?
Does PCI target (native vessel vs bypass graft) affect mortality in NSTEMI patients with prior CABG compared to those without prior CABG?
Answers are grounded in this paper and cite their sources.
In NSTEMI patients with prior CABG, PCI to either native vessels or bypass grafts yields similar adjusted short- and mid-term outcomes compared to PCI in patients without prior CABG.
HomeCirculation: Cardiovascular InterventionsVol. 11, No. 11Outcomes of Percutaneous Coronary Intervention in Non–ST-Segment–Elevation Myocardial Infarction Patients With or Without Prior Coronary Bypass Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBOutcomes of Percutaneous Coronary Intervention in Non–ST-Segment–Elevation Myocardial Infarction Patients With or Without Prior Coronary BypassApples, Oranges, and Grapes! Mohamad Alkhouli, MD and Verghese Mathew, MD Mohamad AlkhouliMohamad Alkhouli Division of Cardiology, West Virginia University, Morgantown (M.A.). and Verghese MathewVerghese Mathew Verghese Mathew, MD, Division of Cardiology, Loyola University Chicago Stritch School of Medicine, 2160 S. First Ave, Suite 6232–6234, Maywood, IL 60153. Email E-mail Address: [email protected] Division of Cardiology, Loyola University Chicago Stritch School of Medicine, Maywood, IL (V.M.). Originally published16 Nov 2018https://doi.org/10.1161/CIRCINTERVENTIONS.118.007460Circulation: Cardiovascular Interventions. 2018;11:e007460This article is a commentary on the followingOutcomes Following Percutaneous Coronary Intervention in Non–ST-Segment–Elevation Myocardial Infarction Patients With Coronary Artery Bypass GraftsSee Article by Shoaib et alPatients with prior coronary artery bypass grafting (CABG) constitute a high-risk subgroup of patients presenting with non–ST-segment–elevation myocardial infarction (NSTEMI).1,2 However, limited data are available to inform clinicians on the optimal management of these patients. Two US registry–based studies have shown worse adjusted in-hospital and long-term outcomes among CABG patients who undergo percutaneous coronary intervention (PCI) to bypass grafts versus those who receive PCI to native coronary vessels.3,4 Nonetheless, these studies included PCIs performed for any indication, with NSTEMI being the reason for PCI in less than one-fourth of patients. In this issue of Circulation: Cardiovascular Interventions, Shoaib et al5 attempt to bridge some of our knowledge gap by specifically investigating the outcomes of PCI in patients with prior CABG who are admitted with NSTEMI.The authors utilized the British Cardiovascular Intervention Society database to identify patients with NSTEMI who underwent PCI between 2007 and 2014. The study cohort (n=205 039 patients) was divided into 3 groups for the comparative analysis: group 1 (PCI to native coronary, no prior CABG), group 2 (PCI to native coronary, prior CABG), and group 3 (PCI to a bypass graft). Patients with prior CABG (groups 2 and 3) were older, less likely to be female, and had a higher prevalence of key morbidities and left ventricle dysfunction compared with patients without prior CABG (group 1). Unadjusted 30-day and 1-year mortality varied among the 3 groups but were highest in group 2. However, after adjusting for baseline characteristics, no significant differences were observed in 30-day and 1-year mortality between the 3 groups. Adjusted rates of in-hospital stroke, bleeding, or major adverse events were also similar across the groups.Additional observations in this study are worth noting: (1) among patients with prior bypass who undergo PCI following an NSTEMI, about half underwent PCI to a native vessel and half receive PCI to a bypass graft, changing modestly over time in favor of treating the native vessel. This is in contrast to US data, where the majority of patients with prior bypass referred for PCI now undergo treatment of a native vessel rather a bypass graft.3,4 (2) Compared with NSTEMI patients without prior CABG in whom radial access was used in 55%, <30% of patients with prior CABG receive PCI via a radial approach regardless of whether a native vessel or bypass graft is treated. (3) There was different utilization of drug-eluting stents in the prior CABG group between patients who received PCI to native vessel versus those who received PCI of a bypass graft (73% versus 68%, P<0.001). Despite earlier evidence against, and then later in favor of drug eluting stent in saphenous vein graft, the recent randomized trial addressing this has shown no incremental benefit of drug-eluting stents over bare-metal stents in bypass graft PCIs.6 (4) Similar to what has observed in other studies from North America, the use of embolic protection devices (EPDs) in native bypass graft interventions in this study was <20%.7 The use of EPDs is still a class I recommendation in the current American College of Cardiology/American Heart Association/Society of Cardiac Angiography and Interventions PCI guidelines based on the compelling evidence from randomized data, demonstrating benefit of use.8 The pattern of infrequent EPD use in this study and other studies, as well as their lack of efficacy in contemporary US registry reports has raised a specter of doubt of the usefulness of EPDs in current practice, although we think that it is possible that infrequent EPD use begets insufficient EPD experience leading to lack of expertise in EPD use, which may negate the benefits that were clearly demonstrated with these devices in earlier randomized trials.These data represent, to date, the largest set of outcomes data of PCI in CABG patients hospitalized with NSTEMI. A novel key finding of this study is percutaneous revascularization in NSTEMI patients with prior CABG is associated with excellent adjusted short and midterm outcomes that are similar to those observed in patients without prior CABG and irrespective of the revascularization target (native vessel versus bypass graft). In attempt to define the relevance of these findings to clinical practice, closer scrutiny is warranted:First, a substantial issue to consider is to understand exactly what population was studied. This is essential to provide a context for interpretation of the study's results and their utility in guiding clinical practice. In this study, the authors utilized a national PCI registry that specifically included NSTEMI patients who underwent PCI; patients who were managed medically and those who were referred for redo-bypass surgery were not captured in this registry. Also, reasons for referral or avoidance of PCI in the overall cohort of prior CABG patients admitted with NSTEMI are not known. In clinical practice, patients at the highest ambient clinical risk are less often referred for higher order (invasive) diagnostics or therapeutics than lower risk patients.9 This paradoxical referral pattern likely stems from our intrinsic aversion to incurring short-term/periprocedural adverse events, despite the observation that high-risk patients likely glean greater absolute long-term benefit. A study by Asrar Ul Haq et al10 suggested that among prior CABG patients with NSTEMI, only a small minority undergo PCI. Khera et al11 also found that prior CABG is a negative predictor of undergoing invasive assessment±PCI in patients admitted with NSTEMI. Hence, examination of highly selected NSTEMI patients who underwent PCI may limit meaningful comparative effectiveness analyses between different PCI strategies.Second, a relevant observation is that the proportion of patients with prior CABG in this study was only 9% overall. This is less than half of the representation of prior CABG patients in large PCI registries in the United States.3,4 Although the denominator (total number of CABG surgeries) is not known, it is possible that the underrepresentation of prior CABG patients in this registry may be related to trans-Atlantic differences in their management, which again may contribute to selection bias in this cohort.Third, the authors undertook multiple measures to adjust for the differences between the 3 groups including risk adjustments for traditional risk factors (age, sex, comorbidities, etc), disease, and procedural-specific factors (access, presence of shock, PCI to left anterior descending or left main surrogated for large myocardium in jeopardy, etc). However, certain biases related to lesion characteristics, the age, degree of degeneration, and prior interventions of treated grafts, and operator experience remain significant and difficult to account for in adjusted analyses. For instance, the presence of a chronic total occlusion in the culprit native artery may sway a nonchronic total occlusion operator towards attempting PCI of the bypass graft. However, a subacute total occlusion of an old vein graft with substantial atherothrombotic burden may direct the operator's attention to the native coronary lesion even if it has nonfavorable features for PCI. Without accounting for such differences, comparing the 3 groups of patients, despite risk adjustment, may be akin to comparing apples, oranges, and grapes.Fourth, an important assumption in this study is that NSTEMIs in prior CABG patients were caused by lesions either in a previously bypassed vessel or in a bypass graft. However, a proportion of patients with prior CABG might have undergone PCI to a native coronary artery that was not previously bypassed. It's uncertain how this issue may have influenced the observed outcomes if at all, but it underscores the various reasons for subsequent events requiring additional revascularization after CABG.Fifth, the authors report 1-year outcomes in 94% of patients. Nonetheless, drawing definitive conclusions on the effectiveness of PCI to native vessel versus to a bypass graft in NSTEMI patients with prior CABG will likely require longer-term follow-up given the significant pathoanatomical differences between the 2 PCI targets.12The findings of this study provide important insights into a common clinical issue where little data are available to guide our decisions. However, they also highlight key remaining questions that interventionalists face in daily practice: How would I treat a patient with NSTEMI because of a bypass graft culprit lesion, in whom both the native coronary and the vein graft lesions appear favorable for PCI? What if the native vessel is tortuous, heavily calcified, or chronically occluded? What if the vein graft is >10 years old, had received multiple previous interventions, or is anastomosed to a small branch vessel or supplies a small myocardial territory?It is unlikely that we will have randomized controlled trial data or adequate granular data from large retrospective registries to address these questions. However, a collaborative multicenter prospective registry, including detailed lesion and PCI characteristics and long-term follow-up of CABG patients, might provide additional insights. Pending such evidence, we propose a pragmatic algorithmic approach incorporating the patient's risk profile, the lesion's characteristics, and the risks/benefit ratio of the various specific management strategies (Figure).Download figureDownload PowerPointFigure. Algorithmic approach to non–ST-segment–elevation myocardial infarction (NSTEMI) in patients with prior coronary artery bypass grafting (CABG). *Consider referral to high-risk percutaneous coronary intervention (PCI) operator if no local expertise; consider medical therapy verses redo bypass as an alternative.DisclosuresNone.FootnotesThe opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.https://www.ahajournals.org/journal/circinterventionsVerghese Mathew, MD, Division of Cardiology, Loyola University Chicago Stritch School of Medicine, 2160 S. First Ave, Suite 6232–6234, Maywood, IL 60153. Email Verghese.[email protected]eduReferences1. Labinaz M, Kilaru R, Pieper K, Marso SP, Kitt MM, Simoons ML, Califf RM, Topol EJ, Armstrong PW, Harrington RA. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial.Circulation. 2002; 105:322–327.LinkGoogle Scholar2. Mathew V, Gersh B, Barron H, Every N, Tiefenbrunn A, Frederick P, Malmgren J. Inhospital outcome of acute myocardial infarction in patients with prior coronary artery bypass surgery.Am Heart J. 2002; 144:463–469.CrossrefMedlineGoogle Scholar3. Brilakis ES, O'Donnell CI, Penny W, Armstrong EJ, Tsai T, Maddox TM, Plomondon ME, Banerjee S, Rao SV, Garcia S, Nallamothu B, Shunk KA, Mavromatis K, Grunwald GK, Bhatt DL. Percutaneous coronary intervention in native coronary arteries versus bypass grafts in patients with prior coronary artery bypass graft surgery: insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.JACC Cardiovasc Interv. 2016; 9:884–893. doi: 10.1016/j.jcin.2016.01.034CrossrefMedlineGoogle Scholar4. Brilakis ES, Rao SV, Banerjee S, Goldman S, Shunk KA, Holmes DR, Honeycutt E, Roe MT. Percutaneous coronary intervention in native arteries versus bypass grafts in prior coronary artery bypass grafting patients: a report from the National Cardiovascular Data Registry.JACC Cardiovasc Interv. 2011; 4:844–850. doi: 10.1016/j.jcin.2011.03.018CrossrefMedlineGoogle Scholar5. Shoaib A, Kinnaird T, Curzen N, Kontopantelis E, Ludman P, de Belder M, Rashid M, Kwok CS, Nolan J,Zaman A, Mamas MA. Outcomes following percutaneous coronary intervention in non–ST-segment–elevation myocardial infarction patients with coronary artery bypass grafts.Circ Cardiovasc Interv. 2018; 11:e006824. doi: 10.1161/CIRCINTERVENTIONS.118.006824LinkGoogle Scholar6. Brilakis ES, Edson R, Bhatt DL, Goldman S, Holmes DR, Rao SV, Shunk K, Rangan BV, Mavromatis K, Ramanathan K, Bavry AA, Garcia S, Latif F, Armstrong E, Jneid H, Conner TA, Wagner T, Karacsonyi J, Uyeda L, Ventura B, Alsleben A, Lu Y, Shih MC, Banerjee S; DIVA Trial Investigators. Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial.Lancet. 2018; 391:1997–2007. doi: 10.1016/S0140-6736(18)30801-8CrossrefMedlineGoogle Scholar7. Paul TK, Bhatheja S, Panchal HB, Zheng S, Banerjee S, Rao SV, Guzman L, Beohar N, Zhao D, Mehran R, Mukherjee D. Outcomes of saphenous vein graft intervention with and without embolic protection device: a comprehensive review and meta-analysis.Circ Cardiovasc Interv. 2017; 10:e005538. doi: 10.1161/CIRCINTERVENTIONS.117.005538LinkGoogle Scholar8. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.Circulation. 2011; 124:e574–e651. doi: 10.1161/CIR.0b013e31823ba622LinkGoogle Scholar9. Zia MI, Goodman SG, Peterson ED, Mulgund J, Chen AY, Langer A, Tan M, Ohman EM, Gibler WB, Pollack CV, Roe MT. Paradoxical use of invasive cardiac procedures for patients with non-ST segment elevation myocardial infarction: an international perspective from the CRUSADE Initiative and the Canadian ACS Registries I and II.Can J Cardiol. 2007; 23:1073–9.CrossrefMedlineGoogle Scholar10. Asrar Ul Haq M, Rudd N, Mian M, Castles A, Mogilevski T, Mutha V, Van Gaal WJ. Predictors and outcomes of early coronary angiography in patients with prior coronary artery bypass surgery presenting with non-ST elevation myocardial infarction.Open Heart. 2014; 1:e000059.CrossrefMedlineGoogle Scholar11. Khera S, Kolte D, Aronow WS, Palaniswamy C, Subramanian KS, Hashim T, Mujib M, Jain D, Paudel R, Ahmed A, Frishman WH, Bhatt DL, Panza JA, Fonarow GC. Non-ST-elevation myocardial infarction in the United States: contemporary trends in incidence, utilization of the early invasive strategy, and in-hospital outcomes.J Am Heart Assoc. 2014; 3:e000995. doi: 10.1161/JAHA.114.000995LinkGoogle Scholar12. Chen LY, Lennon RJ, Grantham JA, Berger PB, Mathew V, Singh M, Holmes DR, Rihal CS. In-hospital and long-term outcomes of multivessel percutaneous coronary revascularization after acute myocardial infarction.Am J Cardiol. 2005; 95:349–354. doi: 10.1016/j.amjcard.2004.09.032CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesOutcomes Following Percutaneous Coronary Intervention in Non–ST-Segment–Elevation Myocardial Infarction Patients With Coronary Artery Bypass GraftsAhmad Shoaib, et al. Circulation: Cardiovascular Interventions. 2018;11 November 2018Vol 11, Issue 11 Advertisement Article InformationMetrics © 2018 American Heart Association, Inc.https://doi.org/10.1161/CIRCINTERVENTIONS.118.007460PMID: 30571220 Originally publishedNovember 16, 2018 Keywordscoronary artery bypassEditorialsmyocardial infarctiondrug-eluting stentspercutaneous coronary interventionPDF download Advertisement SubjectsCardiovascular SurgeryCatheter-Based Coronary and Valvular InterventionsPercutaneous Coronary Intervention
No takes yet. Share an insight, caveat, or question.
Alkhouli et al. (2018) conducted an editorial in Non-ST-Segment-Elevation Myocardial Infarction (NSTEMI) (n=205,039). PCI in patients with prior CABG vs. PCI in patients without prior CABG was evaluated on 30-day and 1-year mortality. Percutaneous revascularization in NSTEMI patients with prior CABG was associated with adjusted 30-day and 1-year mortality similar to patients without prior CABG, regardless of the target vessel.
Synapse has enriched 10 related papers. Consider them for comparative context: